Loading…
Reported covered position: Rep. Visclosky, LA & LD (until 1991)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2017 · fourth_quarter · Q4
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Source: Senate LDA
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Combination Drug Development Incentive Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Combination Drug Development Incentive Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Helping Families in Mental Health Crisis Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Helping Families in Mental Health Crisis Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to and implementation of the Affordable Care Act, including biologics; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; S.2295, Patient Safety & Generic Labeling Improvement Act; drug shortages; Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
Generic Drug Application Review Fairness Act of 2012
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; and S. 369, Preserve Access to Affordable Generics Act.
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Patent Reform Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Promoting Innovation and Access to Life-Saving Medicine Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S. 301, Physicians Payments Sunshine Act of 2009; H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; H.R. 1427 & S. 726, Promoting Innovation & Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to the "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA")
Pathway for Biosimilars Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S. 301, Physicians Payments Sunshine Act of 2009; H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; H.R. 1427 & S. 726, Promoting Innovation & Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to the "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA")
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
2017 · third_quarter · Q3
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2017 · second_quarter · Q2
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2017 · first_quarter · Q1
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · fourth_quarter · 4A
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · fourth_quarter · Q4
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · third_quarter · Q3
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · second_quarter · Q2
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · first_quarter · Q1
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · fourth_quarter · Q4
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · third_quarter · Q3
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · second_quarter · Q2
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · first_quarter · Q1
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · fourth_quarter · Q4
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · third_quarter · Q3
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · second_quarter · Q2
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · first_quarter · Q1
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · fourth_quarter · Q4
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · third_quarter · Q3
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · second_quarter · Q2
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · first_quarter · 1A
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · first_quarter · Q1
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · fourth_quarter · Q4
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to and implementation of the Affordable Care Act, including biologics; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; S.2295, Patient Safety & Generic Labeling Improvement Act; drug shortages; Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act
Filing targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · third_quarter · Q3
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · second_quarter · Q2
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2012 · first_quarter · Q1
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · fourth_quarter · Q4
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals; S. 1357, Affordable Medicines Utilization Act of 2011.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · third_quarter · Q3
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals; S. 1357, Affordable Medicines Utilization Act of 2011.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · second_quarter · Q2
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals.
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2011 · first_quarter · Q1
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011.
Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · fourth_quarter · Q4
H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · 3A
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · 3A
H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · third_quarter · Q3
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · second_quarter · Q2
H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009
H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2010 · first_quarter · Q1
S. 301, Physicians Payments Sunshine Act of 2009; H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; H.R. 1427 & S. 726, Promoting Innovation & Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to the "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA")
H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; and S. 369, Preserve Access to Affordable Generics Act.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2009 · fourth_quarter · Q4
H.R. 3590, "Patient Protecton and Affordable Care Act of 2009", and H.R. 3962, "Affordable Health Care for America" (provisions relating to pharmaceuticals).
S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2009 · third_quarter · Q3
H.R. 3200, "America's Affordable Health Choices Act" and Senate Finance Committee healthcare reform proposal (provisions relating to pharmaceuticals).
S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2009 · second_quarter · Q2
Healthcare reform draft legislative proposals, including the Affordable Health Choices Act (Senate draft) - provisions relating to pharmaceuticals.
S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; and H.R. 1548, Pathway for Biosimilars Act; legislation and proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2009 · first_quarter · Q1
S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; and H.R. 1548, Pathway for Biosimilars Act; legislation and proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2008 · fourth_quarter · Q4
Proposals relating to prescription drug anti-counterfeiting efforts. H.R. 5839 - Safeguarding America's Pharmaceuticals Act of 2008. S. 2029 - Physician Payments Sunshine Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2008 · third_quarter · Q3
Proposals relating to prescription drug anti-counterfeiting efforts. H.R. 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S. 2029 - Physician Payments Sunshine Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2008 · second_quarter · Q2
Proposals relating to prescription drug anti-counterfeiting efforts. H.R. 5839 - Safeguarding Americas Pharmaceuticals Act of 2008 S. 2029 - Physicians Payments Sunshine Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2008 · first_quarter · 1A
Proposals relating to prescription drug anti-counterfeiting efforts. H.R. 5839 - Safeguarding Americas Pharmaceuticals Act of 2008.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2008 · first_quarter · Q1
Proposals relating to prescription drug anti-counterfeiting efforts. H.R. 5839 - Safeguarding Americas Pharmaceuticals Act of 2008.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
H.R. 3590, Patient Protection & Affordable Care Act and H.R. 4872, Healthcare & Education Affordability Reconciliation Act (provisions relating to pharmaceuticals).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)